Follicular lymphoma · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
Ibritumomab tiuxetan protocol Variant #18 Partial | — | — | 8d | 36.5 mo | — | 1 | — | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | — | — | 1 | — | 2 |
131Iodine-Tositumomab monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Observation Partial | — | — | — | 31.3 mo | — | — | — | 4 |
Placebo Partial | — | — | — | — | — | — | — | 1 |
6 of 6 regimens shown